Licensing deals
AstraZeneca Buys 22% of Cellectis in Bold Cell, Gene Therapy Venture
AstraZeneca is making a significant move to collaborate with Cellectis, despite Cellectis discontinuing its multiple myeloma CAR-T program just five ...
Prelude Focuses on SMARCA in AbCellera Deal and Trims Its Portfolio by Dropping Two Phase 1 Candidates
Prelude Therapeutics is undergoing a strategic shift, significantly streamlining its clinical pipeline to focus on the promising potential of its ...
Elektrofi lands $20M from Eli Lilly for subcutaneous drug partnership
Eli Lilly is collaborating with Elektrofi, a drug delivery specialist, to explore the potential of Elektrofi’s microparticle formulation technology in ...
Merck and Daiichi join forces to develop novel cancer drugs in $22B deal
In a strategic move, Merck & Co. has solidified its position in the thriving field of antibody-drug conjugates (ADCs) through ...
Basilea buys clinical-stage antifungal from Eisai, advances its anti-infective strategy
Basilea Pharmaceutica is making a strategic move to bolster its anti-infective pipeline, this time with a $2 million investment in ...
Roche partners with Monte Rosa to develop molecular glue drugs for cancer
In a dynamic move, Roche has forged its second major agreement in the realm of molecular glue technology, this time ...
Sotio inks $740M deal with Synaffix for ADC technology after lead drug setback
In a strategic move following the recent setback in its IL-15 asset trials, Sotio Biotech has embarked on an ambitious ...
Evommune abandons EVO101, a topical IRAK4 inhibitor, for atopic dermatitis
Evommune, a California-based biotech company, has made the strategic decision to discontinue its sole clinical-stage asset, EVO101, following a thorough ...
Takeda licenses AcuraStem’s antisense drug for ALS targeting PIKFYVE
As scientific research continues to underscore the potential of targeting the PIKFYVE enzyme in the quest to combat amyotrophic lateral ...
Vertex partners with Septerna to develop GPCR-targeting drugs for rare diseases
Septerna, a biotech company, has secured an additional $47.5 million in funding through a licensing agreement with Vertex, a prominent ...
